Today 60 participants from all over The Netherlands joined a crash course on drug development at Utrecht Science Park. The course was organized by Kinesis Pharma and supported by CBG|MEB, Utrecht Science Park foundation and HollandBIO.
The course provided different aspects of drug development like drug development overview, pharmaceutical development, non-clinical development and early clinical development, up to Clinical Proof of Concept. The differences between new biologics entities versus new chemical entities were also highlighted in the course.
Two speakers from the Utrecht Science Park community introduced practical examples of development processes, Wietse Mulder, CEO of GenDx talked about the entrepreneurship of development and Lex Bakker, CDO of Merus, about bispecific antobdy development.
For a description of the different topics discussed during the drug development course, please visit the website on the Kinesis Pharma site at http://www.kinesis-pharma.com/drug-development-course-info.html or contact Perry Verzaal Perry.Verzaal@Kinesis-Pharma.com.